Paying for Cures: Creative Payment, Reimbursement, Market Access Models and Defining Value in the CGT Space

18 Jan 2023
Commercializing the Therapies of the Future Track

3:30pm Chair Introduction & Overview

Mark Truscheim, Strategic Director, MIT NEWDIGS


3:45pm Presentation: Defining Value and Global Access Pathways for Gene Therapies

• Demonstrating value of gene therapies within the current HTA context
• Scaling access models for 21st century medicines beyond traditional markets
• Must win integrated access capabilities to scale and commercialize

Tay Salimullah, Vice President, Head of Global Value and Access, Novartis Gene Therapies


4:00pm Presentation: The Role of Outcome-Based Payment Models in Facilitating Access to Gene Therapies

Considering the conceptual framework for establishing when an outcome-based payment model could be relevant for facilitating access & the relevance of outcome-based models for drugs which have already demonstrated compelling efficacy in the clinical trials

Andrew Olaye, Executive Director, Market Access, Orchard Therapeutics


4:15pm Presentation: Using Outcomes-Based Financial Solution to Address Health Payer Affordability & Performance Uncertainty Needs in the Context of Advanced Therapies & Other Precision Medicines

Lucas De Breed, Founder, August Care


4:30pm Closing Panel with Q&A

With all session participants


Andrew Olaye
Executive Director, Market Access & Partnerships EMEA
Orchard Therapeutics
Mark Trusheim
Strategic Director, NEWDIGS Initiative Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
Tay Salimullah
Vice President, Head of Global Value & Access, Novartis Gene Therapies